A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the ...

Pfizer's former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company's ...

Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...

Black Diamond Therapeutics is cutting an unspecified number of workers, including several executives, and making changes to ...

Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...

As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...

As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...

Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over ...

Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...